Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | CHIEF MEDICAL OFFICER | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 620 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Tax withholding · Disposed 24 · Balance 620 F1: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 00:50 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 24 | $1.30 | $31.20 |
DisclosureSEC source: 0001821605-26-000006 · ownership.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2026 pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 18 | $1.10 | $19.80 |
DisclosureSEC source: 0001821605-26-000004 · ownership.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 18 shares of common stock in connection with shares that vested on February 15, 2026 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:18 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 27,737 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001821605-26-000002 · ownership.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,737 Underlying: Common Stock · 27,737 shares Expires 2036-02-01 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:49 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 51 | $4.06 | $207.06 |
DisclosureSEC source: 0001821605-25-000006 · wk-form4_1757710145.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662 F1 · kind: The reporting person is reporting the withholding by the Issuer an aggregate of 51 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer an aggregate of 51 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:58 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 24 | $3.69 | $88.56 |
DisclosureSEC source: 0001411690-25-000054 · wk-form4_1748991515.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 713 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 24 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:45 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 6,966 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001411690-25-000026 · wk-form4_1742337909.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,966 Underlying: Common Stock · 6,966 shares Expires 2035-03-13 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 23:56 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 18 | $5.73 | $103.14 |
DisclosureSEC source: 0001411690-25-000016 · wk-form4_1740009400.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 18 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 18 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On January 24, 2025, the common stock of Bionano Genomics, Inc. split 1-for-60, resulting in the reporting person's ownership of 44,568 less shares of common stock. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:11 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 3,075 | $0.48 | $1,476.00 |
DisclosureSEC source: 0001411690-24-000052 · wk-form4_1726258263.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,323 F1 · kind: The reporting person is reporting the withholding by the Issuer an aggregate of 3,075 shares of common stock that vested on September 11, 2024, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer an aggregate of 3,075 shares of common stock that vested on September 11, 2024, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: Includes 153 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 10, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:40 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-24-015619 · form4-06052024_090611.xml · derivative · entry 2 Chaubey Alka · CIK 0001821605 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-06-02 F4 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:40 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015619 · form4-06052024_090611.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,245 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · shares: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date. F3 · balance_after: Includes 150 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 9, 2023 and 608 shares acquired under the ESPP from previous years. Read SEC document |
| February 15, 2024 Filed Mar 5, 2024 22:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 1,081 | $1.27 | $1,372.87 |
DisclosureSEC source: 0001415889-24-006811 · form4-03052024_100328.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,487 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,081 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,081 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On August 4, 2023, the common stock of Bionano Genomics, Inc. split 1-for-10, resulting in the reporting person's ownership of 112,315 less shares of common stock. F3 · balance_after: Includes 89 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 12, 2023. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 21:26 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050185 · doc4.xml · derivative · entry 2 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-09-17 F2 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of September 11, 2023 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 21:26 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050185 · doc4.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,794 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:21 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-010919 · doc4.xml · derivative · entry 2 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2033-02-14 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:21 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010919 · doc4.xml · nonDerivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,794 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 2,285 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 2,509 shares acquired under the ESPP on December 10, 2022. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 02:07 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-22-010052 · doc4.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:33 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024792 · doc4.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:41 UTC Amendment | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049554 · doc4a.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-09-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:43 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049301 · doc4.xml · derivative · entry 1 Chaubey Alka · CIK 0001821605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-09-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on August 31, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.